South Dakota loses federal funds for prison rape elimination amid fears of national impact
The South Dakota Department of Corrections has lost access to more than $25,000 in federal funding meant to aid in the investigation and prevention of sexual assaults in prisons and jails.
The state Bureau of Finance and Management publishes a rundown, updated weekly, of dollars lost to the state through Trump administration cuts. The latest list includes a loss of $25,332 in 'strategic support' money for compliance with the federal Prison Rape Elimination Act.
The act requires prisons and jails to document sexual assaults behind bars, protect victims who report incidents and ensure adequate safeguards are in place to prevent assaults.
The lost money would have been a second-year award in a two-year grant. The state already received $28,419.
The finance bureau's newest spreadsheet lists $23.7 million in total federal funding lost across various state agencies and projects since the start of the Trump administration.
The DOC says it doesn't actually need the lost federal dollars to comply with the federal law on sexual assaults in prisons. As of this week, the agency hadn't spent all the money from the first grant award.
Corrections spokesman Michael Winder told South Dakota Searchlight that the agency spent about $16,000 from the first year's funding for 'educational literature and training.'
That material included wall posters instructing prisoners on how to report sexual assaults, which listed addresses for anonymous reporting and the number to dial from inmate tablets to report an assault. The department also printed 'no means no' posters, six-step staff procedure cards outlining what to do when an inmate reports a sexual assault, and pamphlets on the rape elimination act for inmates and their friends and family members.
The grant was awarded to help the department comply with the law, and Winder said it now does. He said South Dakota's facilities are 'continuously audited' for compliance with the federal statute. The remaining $12,000 from 2023, he said, will be used 'to provide continued training and advancement for staff who respond, investigate, and provide continued care for victims of sexual violence within the correctional facilities.'
The state penitentiary's most recent federal audit was finalized in January. The report found no deficiencies. Audits of each state correctional facility since 2019, as listed on the department's website, showed no deficiencies.
In 2023, the most recent year for which data are available, there were 22 substantiated sexual assault reports in South Dakota prisons.
That was 22 out of 148 investigations tied to the Prison Rape Elimination Act. The department declined to offer details on the substantiated incidents, citing exemptions in South Dakota open records law for law enforcement records or records that could endanger others, as well as a provision in the act that bars the release of information on individual incidents.
That most recent annual report notes that the department 'began tracking and reporting investigations in a consistent and efficient manner' in 2023.
The loss of the remaining $25,332 for South Dakota was part of the fallout from a decision by the Trump administration to cancel a host of grants related to the Prison Rape Elimination Act Resource Center.
The cuts effectively shut down the resource center for a short period of time. Until the change, the nonprofit organization had dozens of employees, laboring under a collaborative agreement with the U.S. Department of Justice.
Overdose deaths, gang violence draw charges in some — not all — recent prison incidents
Many of them worked to review the audits required of every correctional facility in the U.S. every three years, and served as a resource to connect prisons and jails nationwide with partners who could help them do things like train officers on how to handle sexual assault reports.
A California-based nonprofit called Just Detention International is among the organizations that relied on and worked with the resource center. Its mission is tied specifically to sexual assaults and harassment in correctional settings.
In South Dakota, the group worked with the Rosebud Sioux Tribe to build a compliant sexual assault prevention and reporting framework for a juvenile detention facility. It's also listed as a resource for victims in the most recent penitentiary audit for South Dakota.
Linda McFarlane, Just Detention's executive director, told South Dakota Searchlight that some staff at the resource center have returned since April, when the grants for states and the resource center were rescinded.
All the audits conducted across the U.S. since 2022 remain archived on the resource center website, but McFarlane worries the pared-down staff won't be able to review them. She's also troubled that the funding cuts removed the staff that trained investigators and connected local coordinators with resources.
'Part of the problem was that this message was sent, that PREA is no longer taken seriously,' McFarlane said. 'I think people misunderstood the defunding of the PREA Resource Center to mean the law was no longer in effect. And that is absolutely not true.'
McFarlane was glad to hear that South Dakota intends to continue adhering to the law, but she worries that jailers who may have never taken the law seriously will feel empowered to ignore it.
'We heard from survivors and from currently incarcerated people that this felt like a huge slap in the face, that the government was signaling that they no longer take their safety seriously,' McFarlane said. 'And from within the corrections departments, the people who take it seriously were panicked.'
The former director of the resource center, Dana Shoenberg, posted on LinkedIn that the funding cut had 'scattered' its team into different jobs around the country, but said she hopes they or others continue to work 'to fulfill PREA's promise of eliminating sexual abuse in confinement.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Antonia Hylton cited reporting from the summit that suggested Karoline Leavitt looked frightened after meeting with Putin.
MSNBC host Antonia Hylton has suggested that President Donald Trump's aides, particularly Press Secretary Karoline Leavitt, may have been 'frightened' by what they had witnessed during the president's meeting with Russian President Vladimir Putin. On Saturday night's episode of MSNBC's The Weekend: Primetime, Hylton spoke to former U.S. Ambassador to Russia Michael McFaul—an Obama appointee—about Trump's summit with Putin in Anchorage on Friday. 'A lot of the press corps that was there, they reported in the minutes and hours after the presser that they saw members of the administration, like Karoline Leavitt, look ashen, almost frightened after what they had seen behind closed doors. What did that indicate to you?' Hylton asked McFaul.
Yahoo
an hour ago
- Yahoo
Why Investors Were So Fired Up About First Solar Stock on Friday
Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool


New York Times
an hour ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.